Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy.

Abstract

PURPOSES:

The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers. However, there is currently no information available on the rate of Her-2 positivity and the relapse-free survival (RFS) stratified by Her-2 status in stage 2/3 patients.

METHODS:

The Her-2 status, defined by the current standard method, was examined in 100 gastric cancer patients who underwent curative D2 surgery, who were pathologically diagnosed with stage 2/3 cancer, and received adjuvant S-1 chemotherapy between June 2002 and December 2011.

RESULTS:

Ten of the 100 patients were Her-2 positive. Her-2-positive status was more frequently seen in tumors with a differentiated histology. The 5-year RFS rate was 56.3 % in Her-2-positive cases, and 48.8 % in Her-2 negative cases, which was not significantly different (P = 0.786).

CONCLUSIONS:

The Her-2-positive rate for stage 2/3 gastric cancer patients was low, at only 10 %. Although the RFS was not significantly different based on the Her-2 status, the low positive rate made interpretation difficult. A multi-center study with a large sample size is necessary to clarify the prognostic impact of Her-2 in stage 2/3 gastric cancer patients.

• Authors: Toru Aoyama, Takaki Yoshikawa, Yohei Miyagi, Yoichi Kameda, Junya Shirai, Tsutomu Hayashi, Haruhiko Cho, Takashi Oshima, Norio Yukawa, Yasushi Rino, Munetaka Masuda, Akira Tsuburaya
• Journal: Surgery today (Surg Today) Vol. 43 Issue 12 Pg. 1390-7 (Dec 2013) ISSN: 1436-2813 [Electronic] Japan
• PMID: 23512532 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Adenocarcinoma (genetics, mortality, pathology, therapy)
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Disease-Free Survival
• Drug Combinations
• Gastrectomy (methods)
• Humans
• Neoplasm Staging
• Oxonic Acid (administration & dosage)
• Prognosis
• Receptor, ErbB-2 (metabolism)
• Stomach Neoplasms (genetics, mortality, pathology, therapy)
• Tegafur (administration & dosage)